−Removed: We know of no material
−Removed: pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company or our subsidiary
−Removed: is a party or of which any of their property is subject.
−Removed: There are no proceedings in which any of our directors, officers or affiliates,
−Removed: or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or has a material interest
−Removed: adverse to our or our subsidiary’s interest.
−Removed: SAFETY DISCLOSURES
+Added: LEGAL PROCEEDINGS
+Added: The Company is subject to claims and legal proceedings
+Added: that arise during the course of business.
+Added: The Company is currently subject to the following lawsuits:
+Added: 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
+Added: The complaint
+Added: is captioned Blum v.
+Added: Anavex Life Sciences, Corp.
+Added: et al., case number 1:24-cv-01910, and it named the Company and Christopher Missling
+Added: as Defendants.
+Added: The complaint alleges violations of the Securities and Exchange Act of 1934 associated with disclosures and statements
+Added: made with respect to certain clinical trials for ANAVEX ® 2-73 related to Rett syndrome (the “March 2024 Complaint”).
+Added: At a hearing on or about June 13, 2024, the Court named another purported Company shareholder, Quintessa Huey, as lead plaintiff with
+Added: respect to the March 2024 Complaint.
+Added: An Amended Complaint was filed by the appointed lead plaintiff on July 12, 2024, which asserts allegations
+Added: related to purported violations of Section 10(b) of the Securities Exchange Act tied to disclosures associated with the same clinical
+Added: trials related to Rett Syndrome, and which names the Company and Christopher Missling as defendants.
+Added: The Amended Complaint seeks unspecified
+Added: damages, as well as costs, including counsel and expert witness fees, on behalf of class of investors who purchased stock of the Company
+Added: on the NASDAQ during the period February 1, 2022 through January 1, 2024.
+Added: The defendants filed a motion to dismiss the complaint.
+Added: The motion to dismiss is fully-briefed and awaiting a decision by the Court.
+Added: On May 8, 2024,
+Added: a similar complaint was filed in the same court by Kenneth Downing (case no.
+Added: 1:2024-cv-03529), a purported shareholder of the Company,
+Added: against the same defendants as the March 2024 Complaint.
+Added: The defendants filed a motion to dismiss the complaint.
+Added: Plaintiff Downing voluntarily
+Added: dismissed his complaint subsequent to the filing of the motion to dismiss.
+Added: May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), Christopher Missling, and members of the Company’s
+Added: Board of Directors in the U.S.
+Added: District Court for the District of Nevada by another purported shareholder named Denise Deangelis.
+Added: complaint asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a) of the Securities Exchange
+Added: Act regarding the same or similar allegations at issue in the two purported class action lawsuits related to disclosures and statements
+Added: made about certain clinical trials related to Rett Syndrome.
+Added: The parties are currently due to file a proposed schedule for the anticipated
+Added: motion to dismiss by the Company and Christopher Missling (the other named defendants have not been served with the complaint) on or before
+Added: January 15, 2025.
+Added: know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
+Added: to which our Company or our subsidiaries are a party or of which any of their property is subject.
+Added: There are no other proceedings in which
+Added: any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
+Added: of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries’ interest.
+Added: MINE SAFETY DISCLOSURES
Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.